NovAccess Global Inc. (XSNX)
OTCMKTS · Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
Aug 19, 2026, 4:00 PM EST
NovAccess Global Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
12.33K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | - | - | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ObsEva | 19.64M |
| GeneLink | 1.58M |
| Syros Pharmaceuticals | 386.00K |
| Bioasis Technologies | 199.01K |
| Health Sciences Group | 69.31K |
| NanoLogix | 1.27K |
| Navidea Biopharmaceuticals | 610.00 |
NovAccess Global News
- 2 years ago - NovAccess Global files patent with Cedars-Sinai - TheFly
- 2 years ago - NovAccess Global Advisory on Annual Meeting of Shareholders - Accesswire
- 2 years ago - NovAccess Global announces license to advance immunotherapy platform - TheFly
- 2 years ago - NovAccess Global Announces New License to Advance its Immunotherapy Platform - Accesswire
- 2 years ago - NovAccess Global says financing transaction with Sumner remains pending - TheFly
- 2 years ago - NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders - Accesswire
- 2 years ago - NovAccess Global announces $10.7M financing - TheFly
- 2 years ago - NovAccess Global Announces $10.7 Million Financing - Accesswire